TCTR20210209001招募中不适用
Predictors of Trastuzumab-induced Cardiotoxicity in Breast Cancer Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- Female
入选标准
- •Diagnosed with breast cancer with HER-2 positive and treated with Trastuzumab
- •Available of left ventricular function data during trastuzumab therapy
排除标准
- •LVEF < 50% before trastuzumab therapy
- •Severe valvular heart disease
- •Prior history of chemotherapy for other cancers
研究者
相似试验
已完成
不适用
Prediction of trastuzumab-induced cardiotoxicity using transthoracic echocardiography and cardiac biomarkers in patients with gastric cancerCancer therapeutics-related cardiac dysfunctionJPRN-UMIN000030429Cancer Institute Hospital48
招募中
不适用
Can an MRI scan show early signs of medication-related changes to the heart in patients with breast cancer treated with trastuzumab?Trastuzumab-associated cardiomyopathyInjury, Occupational Diseases, PoisoningISRCTN83167415Working Group Cardiac MRI @ Charité University Medicine Berlin & HELIOS Hospital Berlin-Buch30
终止
2 期
Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance ImagingCancer, BreastLV DysfunctionNCT01436604Centre Francois Baclesse19
进行中（未招募）
不适用
Efficacy and toxicity of Trastuzumab at the maintaining dose of 1 mg/kg/week versus the standard dose of 2 mg/kg/week in combination with chemotherapy in metastatic breast cancer patients. A phase III multicenter study. - Dose optimization of TrastuzumabEUCTR2007-006060-29-ITIST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
Unknown
不适用
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer PatientsCardiac ToxicityAntitumor DrugsBreast CancerNCT04962425Peking University Third Hospital240